Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA safety_alert · 2014-10-24European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig
EMA recommends additional measures to reduce the risk of blood vessel blockage with Iclusig (ponatinib), a cancer medicine, to improve patie…
-
EMA safety_alert · 2014-10-10PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommends additional measures to reduce the risk of blood vessel blockage with…
-
EMA safety_alert · 2013-11-08PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig
PRAC provides updates on the risk of serious vascular occlusive events with cancer medicine Iclusig (ponatinib), highlighting safety concern…
-
CLINICAL_TRIALS safety_alert · 2012-09-12Clinical Trial Update: Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
This clinical trial update discusses thromboembolic complications related to asparaginase in children with acute lymphoblastic leukemia trea…